Literature DB >> 2915977

Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure.

M Lenfant1, J Wdzieczak-Bakala, E Guittet, J C Prome, D Sotty, E Frindel.   

Abstract

We report here a five-step purification procedure that led to the isolation from fetal calf bone marrow extract of a tetrapeptide, Ac-Ser-Asp-Lys-Pro (Mr 487), exerting a high inhibitory activity on the proliferation of hematopoietic pluripotent stem cells [defined here as spleen colony-forming units (CFU-S)]. The structure of this molecule was established from amino acid analysis, fast atom bombardment mass spectrometry, and 1H nuclear magnetic resonance spectral data. This structure was confirmed by comparison with the corresponding synthetic molecule, which presents identical physiochemical characteristics and biological properties. Natural and synthetic peptides administered to mice (at a dose of 100 ng per mouse) after one injection of cytosine arabinonucleoside prevent CFU-S recruitment into DNA synthesis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2915977      PMCID: PMC286560          DOI: 10.1073/pnas.86.3.779

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  11 in total

1.  Stimulating factors liberated by treated bone marrow: in vitro effect on CFU kinetics.

Authors:  E Frindel; H Croizat; F Vassort
Journal:  Exp Hematol       Date:  1976-01       Impact factor: 3.084

2.  Inhibitor of stem cell proliferation in normal bone marrow.

Authors:  B I Lord; K J Mori; E G Wright; L G Lajtha
Journal:  Br J Haematol       Date:  1976-11       Impact factor: 6.998

3.  A stimulator of stem cell proliferation in regenerating bone marrow.

Authors:  B I Lord; K J Mori; E G Wright
Journal:  Biomedicine       Date:  1977-07

4.  Stimulating factors and cell recruitment in murine bone marrow stem cells and EMT6 tumours.

Authors:  E Frindel; M Guigon; D Dumenil; M P Fache
Journal:  Cell Tissue Kinet       Date:  1978-07

5.  Inhibition of CFU entry into cycle by a bone marrow extract.

Authors:  E Frindel; M Guigon
Journal:  Exp Hematol       Date:  1977-01       Impact factor: 3.084

6.  Effects of CFS-S inhibitors on murine bone marrow during ARA-C treatment--I. Effects on stem cells.

Authors:  M Guigon; J Enouf; E Frindel
Journal:  Leuk Res       Date:  1980       Impact factor: 3.156

7.  A convenient source of CFU-s inhibitors: the fetal calf liver.

Authors:  M Guigon; J Wdzieczak-Bakala; J Y Mary; M Lenfant
Journal:  Cell Tissue Kinet       Date:  1984-01

8.  Further purification of a CFU-S inhibitor: in vivo effects after cytosine arabinoside treatment.

Authors:  J Wdzieczak-Bakala; M Guigon; M Lenfant; E Frindel
Journal:  Biomed Pharmacother       Date:  1983       Impact factor: 6.529

9.  Protection of mice against lethal doses of 1 beta-D-arabinofuranosylcytosine by pluripotent stem cell inhibitors.

Authors:  M Guigon; J Y Mary; J Enouf; E Frindel
Journal:  Cancer Res       Date:  1982-02       Impact factor: 12.701

10.  Determination of reducing sugars in the nanomole range with tetrazolium blue.

Authors:  C K Jue; P N Lipke
Journal:  J Biochem Biophys Methods       Date:  1985-08
View more
  49 in total

Review 1.  Growth inhibitors: molecular diversity and roles in cell proliferation.

Authors:  K Miyazaki; T Horio
Journal:  In Vitro Cell Dev Biol       Date:  1989-10

2.  The complete sequences of trout (Salmo gairdneri) thymosin beta 11 and its homologue thymosin beta 12.

Authors:  P P Yialouris; B Coles; O Tsitsiloni; B Schmid; S Howell; A Aitken; W Voelter; A A Haritos
Journal:  Biochem J       Date:  1992-04-15       Impact factor: 3.857

3.  Distribution and biological activity ofβ-thymosins.

Authors:  M Mihelić; W Voelter
Journal:  Amino Acids       Date:  1994-02       Impact factor: 3.520

4.  Renal release of N-acetyl-seryl-aspartyl-lysyl-proline is part of an antifibrotic peptidergic system in the kidney.

Authors:  Cesar A Romero; Nitin Kumar; Pablo Nakagawa; Morel E Worou; Tang-Dong Liao; Edward L Peterson; Oscar A Carretero
Journal:  Am J Physiol Renal Physiol       Date:  2018-11-07

5.  AcSDKP: a new potential marker of malignancy of the thyroid gland.

Authors:  Michal Kusinski; Joanna Wdzieczak-Bakala; Jian-Miao Liu; Jerome Bignon; Krzysztof Kuzdak
Journal:  Langenbecks Arch Surg       Date:  2006-01-18       Impact factor: 3.445

6.  Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline.

Authors:  Yanlu Zhang; Zheng Gang Zhang; Michael Chopp; Yuling Meng; Li Zhang; Asim Mahmood; Ye Xiong
Journal:  J Neurosurg       Date:  2016-05-20       Impact factor: 5.115

7.  Antifibrotic effects of N-acetyl-seryl-aspartyl-Lysyl-proline on the heart and kidney in aldosterone-salt hypertensive rats.

Authors:  H Peng; O A Carretero; L Raij; F Yang; A Kapke; N E Rhaleb
Journal:  Hypertension       Date:  2001-02       Impact factor: 10.190

Review 8.  A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme.

Authors:  Kenneth E Bernstein; Frank S Ong; Wendell-Lamar B Blackwell; Kandarp H Shah; Jorge F Giani; Romer A Gonzalez-Villalobos; Xiao Z Shen; Sebastien Fuchs; Rhian M Touyz
Journal:  Pharmacol Rev       Date:  2012-12-20       Impact factor: 25.468

9.  N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo.

Authors:  Dahai Wang; Oscar A Carretero; Xiao-Yi Yang; Nour-Eddine Rhaleb; Yun-He Liu; Tang-Dong Liao; Xiao-Ping Yang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-07-15       Impact factor: 4.733

10.  Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension.

Authors:  Saman Rasoul; Oscar A Carretero; Hongmei Peng; Maria A Cavasin; Jialong Zhuo; Alicia Sanchez-Mendoza; David R Brigstock; Nour-Eddine Rhaleb
Journal:  J Hypertens       Date:  2004-03       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.